In a pharmaceutical context, metabolomics is an underexplored area of research.
Nevertheless, its utility in clinical pathology, biomarker discovery, metabolic subty**, and …

Tuberculosis is a global health dilemma. In 2016, the WHO reported 10.4 million incidences
and 1.7 million deaths. The need to develop new treatments for those infected with …

Background Chagas disease is a neglected tropical disease (NTD) caused by the eukaryotic
parasite Trypanosoma cruzi. The current clinical and preclinical pipeline for T. cruzi is …

Tuberculosis (TB) is a major global health challenge, with approximately 1.4 million deaths
per year. There is still a need to develop novel treatments for patients infected with …

Identification of unique leads represents a significant challenge in drug discovery. This
hurdle is magnified in neglected diseases such as tuberculosis. We have leveraged public …

Purpose Tuberculosis treatments need to be shorter and overcome drug resistance. Our
previous large scale phenotypic high-throughput screening against Mycobacterium …

High-throughput screening (HTS) in whole cells is widely pursued to find compounds active
against Mycobacterium tuberculosis (Mtb) for further development towards new tuberculosis …

There is an urgent need to identify new treatments for tuberculosis (TB), a major infectious
disease caused by Mycobacterium tuberculosis (Mtb), which results in 1.5 million deaths …

The metabolic instability of an antitubercular small molecule CD117 was addressed through
iterative alteration of a key sulfide substituent and interrogation of the effect on growth …

Selecting and translating in vitro leads for a disease into molecules with in vivo activity in an
animal model of the disease is a challenge that takes considerable time and money. As an …